Advertisement

Tumor Biology

, Volume 35, Issue 4, pp 3269–3281 | Cite as

N stages of the seventh edition of TNM Classification are the most intensive variables for predictions of the overall survival of gastric cancer patients who underwent limited lymphadenectomy

  • Jingyu Deng
  • Rupeng Zhang
  • Yuan Pan
  • Baogui Wang
  • Liangliang Wu
  • Xishan Hao
  • Han Liang
Research Article

Abstract

The objective of this study was to explore the prognostic prediction rationality of the seventh edition N stage for gastric cancer (GC) patients who underwent the limited lymphadenectomy. Clinicopathological data of 769 GC patients who underwent the curative resection between 1997 and 2006 were analyzed for demonstration that the seventh edition N stage had the significant superiorities of prognostic prediction to the patients who underwent the limited lymphadenectomy. Although the extent of lymphadenectomy was associated with the overall survival (OS) of gastric cancer (GC) patients, the N stages of the seventh edition of the TNM Classification were identified as the most intensively independent predictors of GC prognosis. Using stratum analysis, the 5-year survival rate of patients who underwent limited lymphadenectomy was observed to be significantly different from that of patients who underwent extended lymphadenectomy, regardless of the extent of lymph node metastasis. Multinomial logistic regression analysis revealed that combining the extents of lymph node metastasis and lymphadenectomy could improve the prediction accuracy of patient survival status. Case control analysis showed that regardless of the extent of lymphadenectomy, the seventh edition N stages featured significant superiority for OS evaluation of GC patients. The seventh edition N stage had the prediction rationality for the OS of GC patients who underwent the limited lymphadenectomy.

Keywords

Stomach Neoplasm Lymph node Metastasis Prognosis 

Notes

Acknowledgments

This study is supported in part by grants from the National Basic Research Program of China (973 Program) 2010CB529301. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of interest

None

Supplementary material

13277_2013_1428_MOESM1_ESM.doc (98 kb)
ESM 1 (DOC 97 kb)

References

  1. 1.
    Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma—2nd English Edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRefGoogle Scholar
  2. 2.
    Sobin LH, Wittekind CH. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. 5th ed. New York: John Wiley & Sons; 1997.Google Scholar
  3. 3.
    Hayashi H, Ochiai T, Suzuki T, Shimada H, Hori S, Takeda A, et al. Superiority of a new UICC-TNM staging system for gastric carcinoma. Surgery. 2000;127:129–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Wu CW, Hsieh MC, Lo SS, Tsay SH, Lui WY, P’eng FK. Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma. Gut. 1996;38:525–7.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Deng JY, Liang H, Sun D, Zhan HJ, Wang XN. The most appropriate category of metastatic lymph nodes to evaluate overall survival of gastric cancer following curative resection. J Surg Oncol. 2008;98:343–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Sobin L, Gospodarowicz M, Wittekind C., editors. TNM classification of malignant tumours seventh edition. International Union Against Cancer (UICC). New York: Wiley; 2009.Google Scholar
  7. 7.
    Deng JY, Liang H, Sun D, Wang D, Pan Y. Suitability of 7th UICC N stage for predicting the overall survival of gastric cancer patients after curative resection in China. A Single Clinical Center Report of New N Stage. Ann Surg Oncol. 2010;17:1259–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Ikeguchi M, Murakami D, Kanaji S, Ohro S, Maeta Y, Yamaguchi KI, et al. Lymph node metastasis of gastric cancer: comparison of Union International Contra Cancer and Japanese systems. ANZ J Surg. 2004;74:852–4.PubMedCrossRefGoogle Scholar
  9. 9.
    D'Ugo D, Pacelli F, Persiani R, Pende V, Ianni A, Papa V, et al. Impact of the latest TNM classification for gastric cancer: retrospective analysis on 94 D2 gastrectomy. World J Surg. 2002;26:672–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Deng J, Liang H, Sun D, Pan Y, Liu Y, Wang DC. Extended lymphadenectomy improvement of overall survival of gastric cancer patients with perigastric node metastasis. Langenbeck Arch Surg. 2011;396:615–23.CrossRefGoogle Scholar
  11. 11.
    Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic lymph node dissection for gastric cancer. N Engl J Med. 2008;359:453–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJH. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.PubMedCrossRefGoogle Scholar
  13. 13.
    Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79:1522–30.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Songun I, Putter H, Kranenbarg EM-K, Sasako M, van de Velde CJH. Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.PubMedCrossRefGoogle Scholar
  15. 15.
    Degiuli M, Sasako M, Ponti A. Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97:643–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. Semin Surg Oncol. 1994;10:12–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Jaehne J, Meyer HJ, Maschek H, Geerlings H, Bruns E, Pichlmayr R. Lymphadenectomy in gastric adenocarcinoma: a prospective and prognostic study. Arch Surg. 1992;127:290–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer. 2002;5:1–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Smith DD, Schwarz RR, Schwartz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-Population Database. JCO. 2005;23:7114–24.CrossRefGoogle Scholar
  20. 20.
    Nitsche U, Maak M, Schuster T, Künzli B, Langer R, Slotta-Huspenina J, et al. Prediction of prognosis is not improved by the seventh and latest edition of the TNM classification for colorectal cancer in a single-center collective. Ann Surg. 2011;254:793–800.PubMedCrossRefGoogle Scholar
  21. 21.
    Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY, Park YO, et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008;112:352–61.PubMedCrossRefGoogle Scholar
  22. 22.
    Deng J, Liang H, Sun D, Zhang R, Zhan H, Wang X. Prognosis of gastric cancer patients with negative node metastasis following curative resection. Outcomes of the Survival and Recurrence. Can J Gastroenterol. 2008;22:835–9.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Ichikura T, Ogawa T, Chochi K, Kawabata T, Sugasawa H, Mochizuki H. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. World J Surg. 2003;27:330–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Bilici A, Ustaalioglu BB, Gumus M, Seker M, Yilmaz B, Kefeli U, et al. Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer? Onkologie. 2010;33:101–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Deng JY, Liang H. Does metastatic lymph node ratio really suit for prognostic prediction of the D1 lymphadenectomy? Ann Surg Oncol. 2010;17:1718.PubMedCrossRefGoogle Scholar
  26. 26.
    Deng J, Liang H. Discussion the applicability of positive lymph node ratio as a proper N-staging for prediction the prognosis of gastric cancer after curative surgery plus extended lymphadenectomy. Ann Surg. 2012;256:e35–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Deng J, Liang H, Sun D, Pan Y. The prognostic analysis of lymph node-positive gastric cancer patients following curative resection. J Surg Res. 2010;161:47–53.PubMedCrossRefGoogle Scholar
  28. 28.
    Seevaratnam R, Bocicariu A, Cardoso R, Mahar A, Kiss A, Helyer L, et al. A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer. 2012;15 Suppl 1:S60–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Danielson H, Kokkola A, Kiviluoto T, Sirén J, Louhimo J, Kivilaakso E, et al. Clinical outcome after D1 vs D2-3 gastrectomy for treatment of gastric cancer. Scand J Surg. 2007;96:35–40.PubMedGoogle Scholar
  30. 30.
    Díaz de Liaño A, Yárnoz C, Artieda C, Aguilar R, Viana S, Artajona A, et al. Results of R0 surgery with D2 lymphadenectomy for the treatment of localized gastric cancer. Clin Transl Oncol. 2009;11:178–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Putchakayala K, Difronzo LA. D2 lymph node dissection improves staging in patients with gastric adenocarcinoma. Am Surg. 2011;77:1326–9.PubMedGoogle Scholar
  32. 32.
    Otsuji E, Kuriu Y, Ichikawa D, Ochiai T, Okamoto K, Hagiwara A, et al. Efficacy of prophylactic extended lymphadenectomy with gastrectomy for patients with node-negative advanced gastric carcinoma. Hepatogastroenterology. 2008;55:755–9.PubMedGoogle Scholar
  33. 33.
    Kikuchi S, Kurita A, Natsuya K, Sakuramoto S, Kobayashi N, Shimao H, et al. First drainage lymph node(s) in gastric cancer: analysis of the topographical pattern of lymph node metastasis in patients with pN-1 stage tumors. Anticancer Res. 2003;23:601–4.PubMedGoogle Scholar
  34. 34.
    Yoshikawa T, Sasako M, Sano T, Nashimoto A, Kurita A, Tsujinaka T, et al. Stage migration caused by D2 dissection with para-aortic lymphadenectomy for gastric cancer from the results of a prospective randomized controlled trial. Br J Surg. 2006;93:1526–9.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Jingyu Deng
    • 1
  • Rupeng Zhang
    • 1
  • Yuan Pan
    • 1
  • Baogui Wang
    • 1
  • Liangliang Wu
    • 1
  • Xishan Hao
    • 1
  • Han Liang
    • 1
  1. 1.Department of Gastric Cancer SurgeryTianjin Medical University Cancer Hospital and City Key Laboratory of Tianjin Cancer CenterTianjinChina

Personalised recommendations